bafetinib
Small moleculeexperimental
Bafetinib (NS-187) is an experimental cancer drug developed by Nippon Shinyaku and licensed to CytRx. It is an inhibitor of Lyn and Bcr-Abl. It reached phase II clinical trials in 2010. — Wikipedia
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2006 (NCT00352677)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase LynINHIBITOR
LYN inhibitor
- Tyrosine-protein kinase ABLINHIBITOR
ABL1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1- Mol. weight
- 576.63 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBafetinib ↗
- ChEMBLCHEMBL206834 ↗
Also known as
- bafetinib
- bafetinib
- bafetinib
- bafetinib
- bafetinib
- cns-9
- cns-9
- inno-406
- inno-406
- inno-406
- inno-406
- ns-187
- ns-187
- ns-187
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01234740 | N/A | Dec 1, 2010 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01215799 | Phase 2 | Aug 1, 2010 | CytRx |
| NCT01144260 | Phase 2 | Jun 1, 2010 | CytRx |
| NCT00352677 | Phase 1 | Jul 1, 2006 | CytRx, University of Texas at Houston |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CytRx | For profit | 3 | 3 | 2 | 2006 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2010 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2006 |
4 organizations
Page 1 / 1